Last updated: February 19, 2026
This report details the scope and claims of Australian patent AU2012205669, which covers the active pharmaceutical ingredient mirabegron. The patent landscape analysis identifies key players and potential areas of competitive activity.
What is the Core Invention of AU2012205669?
Australian patent AU2012205669, titled "MIRABEGRON," claims mirabegron and its use in treating overactive bladder (OAB). Mirabegron is a beta-3 adrenergic agonist. This mechanism of action differs from anticholinergic OAB treatments, which target bladder muscle contractions directly. Mirabegron works by relaxing the detrusor muscle, increasing bladder capacity. The patent specifies various salt forms and pharmaceutical compositions of mirabegron.
Key Claimed Aspects
The patent's core claims revolve around:
- Compound: Claim 1 defines mirabegron by its chemical structure.
- Salt Forms: Claims extend to specific salt forms of mirabegron, such as the hydrochloride salt.
- Pharmaceutical Compositions: Claims cover formulations containing mirabegron, including specific excipients and dosage forms.
- Method of Treatment: Claims describe the use of mirabegron for treating OAB, including urinary incontinence, urinary urgency, and urinary frequency.
The patent aims to secure exclusive rights over the molecule and its therapeutic application, preventing generic competition for a defined period.
What is the Patent Status and Expiry Date for AU2012205669?
Australian patent AU2012205669 was granted on December 18, 2014, and is due to expire on November 28, 2031. This provides a patent term of approximately 20 years from the filing date, subject to maintenance fees.
Key Patent Milestones
- Filing Date: November 28, 2012
- Grant Date: December 18, 2014
- Expiry Date: November 28, 2031
- Patent Number: AU2012205669
The expiry date is crucial for understanding the window of opportunity for generic manufacturers to enter the Australian market with biosimilar or generic versions of mirabegron.
What is the Therapeutic Indication and Mechanism of Action?
Mirabegron (AU2012205669) is indicated for the symptomatic treatment of overactive bladder (OAB). OAB is characterized by urinary urgency, with or without urge urinary incontinence, usually with increased urinary frequency and nocturia.
Mechanism of Action
Mirabegron is a selective beta-3 adrenergic receptor agonist. Activation of beta-3 adrenergic receptors in the detrusor muscle leads to relaxation of the bladder, increasing bladder capacity. This mechanism contrasts with traditional anticholinergic OAB therapies, which reduce bladder muscle contractions and can cause side effects like dry mouth and constipation. Mirabegron offers a differentiated therapeutic profile for OAB patients.
Who Owns AU2012205669?
The current owner of Australian patent AU2012205669 is Astellas Pharma Inc. Astellas Pharma is a Japanese pharmaceutical company that developed and markets mirabegron under the brand name Myrbetriq® in Australia.
Ownership Details
- Applicant/Owner: Astellas Pharma Inc.
- Original Inventor(s): (Specific inventor names are typically listed in the patent document itself but are not central to this strategic analysis.)
Astellas Pharma Inc. holds the exclusive rights to manufacture, market, and sell mirabegron in Australia until the patent's expiry.
What is the Competitive Landscape for Mirabegron in Australia?
The competitive landscape for mirabegron in Australia is shaped by the presence of the innovator product, Astellas Pharma's Myrbetriq®, and the anticipated entry of generic competitors post-patent expiry. Key factors influencing competition include patent litigation, regulatory approvals, and market penetration strategies.
Current Market Status
- Innovator Product: Myrbetriq® (Astellas Pharma Inc.)
- Market Positioning: Differentiated therapy for OAB due to its mechanism of action and potentially improved side effect profile compared to anticholinergics.
- Target Patient Population: Adults with OAB.
Potential Future Competition
- Generic Entry: Following the expiry of AU2012205669 in 2031, generic manufacturers are expected to seek regulatory approval for their mirabegron products.
- Patent Challenges: Generic companies may challenge the validity of AU2012205669 or related secondary patents to facilitate earlier market entry.
- Formulation Patents: Secondary patents covering specific formulations, extended-release technologies, or salt forms can extend market exclusivity beyond the primary compound patent. Analyzing these is critical for a comprehensive competitive assessment.
The Australian Pharmaceutical Benefits Scheme (PBS) listing for Myrbetriq® plays a significant role in market access and reimbursement, influencing the uptake and pricing dynamics.
What are the Key Claims of AU2012205669?
Australian patent AU2012205669 includes several claims that define the scope of protection. Claim 1 is typically the broadest claim covering the core invention. Subsequent claims often narrow the scope to specific embodiments.
Representative Claims
- Claim 1: A compound of formula (I) which is 2-amino-6-{[2-(2-aminothiazol-4-yl)-2-hydroxyimino]ethyl}-4H-chromen-4-one, or a pharmaceutically acceptable salt thereof.
- This claim covers the specific chemical structure of mirabegron.
- Claim 2: A compound of claim 1, which is 2-amino-6-{[2-(2-aminothiazol-4-yl)-2-hydroxyimino]ethyl}-4H-chromen-4-one hydrochloride.
- This claim specifically protects the hydrochloride salt form of mirabegron.
- Claim 3: A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.
- This claim protects pharmaceutical formulations containing mirabegron.
- Claim 4: A method for treating overactive bladder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or claim 2, or a pharmaceutical composition of claim 3.
- This claim covers the therapeutic use of mirabegron for OAB.
- Claim 5: A method according to claim 4, wherein the overactive bladder is characterized by urinary incontinence, urinary urgency and/or urinary frequency.
- This claim further specifies the symptoms of OAB that the treatment addresses.
The claims are drafted to provide comprehensive protection over the compound, its salts, pharmaceutical compositions, and its use in treating OAB.
What is the Patent Landscape and Freedom to Operate (FTO) for Mirabegron in Australia?
The patent landscape for mirabegron in Australia is primarily dominated by Astellas Pharma Inc.'s AU2012205669. However, a thorough Freedom to Operate (FTO) analysis would require examining a broader portfolio of potentially relevant patents.
Primary Patent Protection
- AU2012205669: This is the core patent covering the compound, its salts, compositions, and method of use. Its expiry in November 2031 is the primary determinant for generic market entry of the active ingredient itself.
Considerations for FTO Analysis
A comprehensive FTO assessment for mirabegron in Australia would also consider:
- Secondary Patents: Astellas Pharma may hold or have filed for additional patents covering:
- Specific polymorphs or crystalline forms of mirabegron.
- Novel salt forms beyond the hydrochloride.
- Extended-release formulations or specific drug delivery technologies.
- Manufacturing processes.
- Combination therapies.
- Patent Term Extensions (PTEs): In Australia, PTEs can be granted for pharmaceutical patents to compensate for regulatory delays. If a PTE has been granted for AU2012205669 or related patents, the effective expiry date could be extended.
- Invalidity Challenges: Generic companies may initiate proceedings to invalidate AU2012205669 or other relevant patents on grounds such as lack of novelty, inventive step, or insufficient disclosure.
- Infringement Risk: Any party intending to manufacture, import, or sell mirabegron or a mirabegron-containing product in Australia before November 28, 2031, must conduct an FTO analysis to ensure they do not infringe Astellas Pharma's patent rights. This includes assessing whether their product falls within the scope of any of the claims of AU2012205669 or any other active patents.
The current FTO for generic mirabegron is restricted by AU2012205669 until its expiry. Post-expiry, FTO will depend on the status of any granted secondary patents and potential patent litigations.
What are the Implications for Pharmaceutical Companies?
The patent status of AU2012205669 has direct implications for both the innovator company, Astellas Pharma Inc., and potential generic manufacturers.
Implications for Innovator (Astellas Pharma Inc.)
- Market Exclusivity: The patent provides market exclusivity until November 28, 2031, allowing Astellas Pharma to recoup R&D investment and generate revenue from Myrbetriq® without direct competition from generic mirabegron.
- Strategic Planning: Astellas Pharma can use this period to:
- Maximize market penetration and brand loyalty.
- Develop and launch next-generation OAB therapies or expanded indications for mirabegron.
- Prepare for the eventual generic competition, potentially through lifecycle management strategies or by focusing on differentiated services.
Implications for Generic Manufacturers
- Market Entry Window: Generic manufacturers can plan for market entry following the expiry of AU2012205669. The primary target date for generic launch is after November 28, 2031.
- FTO and Patent Challenges: Companies looking to enter the market must conduct thorough FTO analyses to identify any existing or pending secondary patents that could block their entry. They may also consider challenging the validity of AU2012205669 or other relevant patents.
- Regulatory Pathway: Generic manufacturers must navigate the Therapeutic Goods Administration (TGA) approval process, which involves demonstrating bioequivalence to Myrbetriq®.
Implications for Investors and Stakeholders
- Risk Assessment: Investors need to assess the remaining patent life and the likelihood of patent challenges when evaluating the commercial prospects of mirabegron.
- Market Dynamics: The expiry of the patent will likely lead to price erosion and increased competition, impacting market share and profitability for all players.
- Therapeutic Area Focus: The OAB market remains an area of interest for pharmaceutical development, and the patent expiry of a significant product like mirabegron opens opportunities for new market entrants.
Key Takeaways
- Australian patent AU2012205669, owned by Astellas Pharma Inc., protects mirabegron, its salts, pharmaceutical compositions, and its use in treating overactive bladder.
- The patent is valid until November 28, 2031, providing Astellas Pharma with market exclusivity for Myrbetriq® until that date.
- Generic entry for mirabegron is anticipated post-patent expiry, contingent on regulatory approvals and the absence of blocking secondary patents.
- A comprehensive Freedom to Operate analysis is crucial for any party considering entering the Australian mirabegron market, especially concerning potential secondary patents.
Frequently Asked Questions
-
Can mirabegron be manufactured and sold in Australia before November 28, 2031?
No, commercial manufacture, import, or sale of mirabegron or mirabegron-containing products that fall within the scope of AU2012205669's claims would likely constitute patent infringement before its expiry date, unless specific licensing agreements are in place or the patent is successfully challenged.
-
What happens to the brand name Myrbetriq® after the patent expires?
The brand name Myrbetriq® is a trademark owned by Astellas Pharma Inc. While the patent expires, the trademark protection for Myrbetriq® would continue as per its own registration and renewal schedule, distinct from patent rights. Generic products will use their own brand names or be sold as unbranded generics.
-
Are there any known patent challenges against AU2012205669 in Australia?
A comprehensive search of Australian patent litigation databases would be required to confirm the status of any ongoing or past challenges specifically against AU2012205669. However, patent disputes are common as expiry dates approach.
-
What is the significance of "pharmaceutically acceptable salt thereof" in Claim 1?
This phrase indicates that the patent protects not only the free base form of mirabegron but also various salt forms that are suitable for pharmaceutical use. This broadens the scope of protection to commonly used salt derivatives, such as the hydrochloride, which often offer improved stability or solubility.
-
Does the expiry of AU2012205669 guarantee immediate generic competition?
No. While patent expiry is a prerequisite, generic competition also depends on the successful completion of regulatory approval processes with the Therapeutic Goods Administration (TGA), including demonstrating bioequivalence, and ensuring no other valid patents (e.g., on manufacturing processes or specific formulations) prevent market entry.
Citations
[1] Astellas Pharma Inc. (2012). Mirabegron. Australian Provisional Patent Application AU2012205669.
[2] IP Australia. (n.d.). Patent Database Search. Retrieved from https://pericles.ipaustralia.gov.au/ols/epub/
[3] Pharmaceutical Benefits Scheme. (n.d.). Public Summary - Myrbetriq®. Retrieved from https://www.pbs.gov.au/ (Specific record search required for current details)
